SYRESpyre Therapeutics, Inc.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M

Gross Profit

$19M100.0% margin

Operating Income

-$66M-350.3% margin

Net Income

-$66M-351.1% margin

EPS (Diluted)

$-25.02

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$110M

Total Liabilities

$26M

Stockholders' Equity

$84M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$0	—
Gross Profit	$19M	-$2M	+1253.9%
Operating Income	-$66M	-$81M	+19.4%
Net Income	-$66M	-$81M	+18.7%

SYRE FY 2021 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena